Compare AbbVie Inc (ABBV) vs Sprott Uranium Miners ETF (URNM) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

URNM trades at $54.53, up 2.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF, focused on uranium miners, benefits from growing nuclear energy demand driven by AI power needs and government support, as highlighted in recent news. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.

The outlook for URNM is positive due to structural tailwinds in nuclear energy, but risks include high volatility from commodity prices and concentrated miner exposure. Investors should weigh the bullish technical setup against the lack of transparent valuation metrics and potential sector-specific headwinds.